Andrew Hollman Meyer Sells 13,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total transaction of $731,769.92. Following the transaction, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Janux Therapeutics Stock Up 1.3 %

NASDAQ:JANX opened at $53.92 on Friday. The firm has a market cap of $2.83 billion, a PE ratio of -46.09 and a beta of 3.29. The company’s 50-day moving average price is $54.53 and its two-hundred day moving average price is $47.88. Janux Therapeutics, Inc. has a 12 month low of $7.79 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.50 million. The business’s revenue was down 82.6% on a year-over-year basis. On average, research analysts expect that Janux Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in JANX. Franklin Resources Inc. grew its holdings in Janux Therapeutics by 64.5% during the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after acquiring an additional 7,442 shares during the last quarter. Virtu Financial LLC lifted its position in shares of Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock worth $339,000 after purchasing an additional 2,419 shares in the last quarter. Neo Ivy Capital Management bought a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $940,000. Geode Capital Management LLC increased its holdings in shares of Janux Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Finally, Barclays PLC raised its position in Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JANX has been the topic of a number of recent research reports. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Scotiabank boosted their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research report on Wednesday, December 4th. HC Wainwright raised their target price on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Finally, UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $89.90.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.